Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268151 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00268151 is a Phase 1 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 24 participants.
The verdict
NCT00268151, a Phase 1 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268151
The ClinicalTrials.gov registry entry for NCT00268151 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00268151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268151 about?
NCT00268151 is a clinical study titled "Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer". The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.
What is the current status of trial NCT00268151?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00268151?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00268151?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.